Journal of Clinical Trials

Journal of Clinical Trials
Open Access

ISSN: 2167-0870

+44 20 3868 9735

Tsutomu Nakamura

Laboratory of Molecular and Genetic Information, Institute for Quantitative Biosciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan

  • Mini Review   
    Intestinal Dysbiosis and Probiotics in COVID-19
    Author(s): Yasunari Kageyama, Tetsu Akiyama and Tsutomu Nakamura*

    The COVID-19 pandemic has been an emerging threat to global public health. Several lines of evidence suggest that the causative virus SARS-CoV-2 infects the human intestinal epithelial cells as well as airway epithelial cells, suggesting that the enteric infection of SARS-CoV-2 has destructive effects on the intestinal microbiota and subsequently airway physiology and immunity through the gut-lung axis. Despite the important roles of the gut-lung axis in the antiviral immunity, only limited information is currently available concerning COVID-19-specific changes in the gut microbiome. This review summarizes recent knowledge of intestinal dysbiosis associated with COVID-19 patients and its potential contribution to the respiratory symptoms through the gut-lung axis. We also discuss the possibility of prophylactic and therapeutic use of probiotics in COVID-19, including our ongoing trial.. Read More»
    DOI: 10.35248/2167-0870.20.10.421

    Abstract HTML PDF